• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Parexel forms early-phase alliance with U.K.’s UH Bristol

Parexel forms early-phase alliance with U.K.’s UH Bristol

January 24, 2012
CenterWatch Staff

Parexel International, a Boston-based global biopharmaceutical services provider, has established an alliance with University Hospitals Bristol National Health Service (NHS) Foundation Trust (UH Bristol), one of the largest specialist teaching and research hospital trusts in the United Kingdom.

The UH Bristol agreement continues to expand Parexel’s alliance network, which complements its dedicated team of experts and hospital-based early phase units, providing clients with access to diverse patient populations worldwide in key therapeutic areas.

“UH Bristol is an ideal alliance for us because of its experience in conducting clinical research, access to substantial patient populations and work across multiple therapeutic areas,” said Sy Pretorius, M.D., M.S., M.B.A., corporate vice president and worldwide head of early phase for Parexel. “Our focus is to provide more efficient delivery of better, faster go/no-go decisions.”

Professor David Wynick, research director at UH Bristol, said, “We believe this alliance furthers our objectives to develop collaborative and consultative research partnerships and support research of national and international excellence and innovation.”  

UH Bristol, the region’s largest provider of medical and dental teaching, is a leading research center and one of the largest acute NHS trusts in the country. It employs over 7,900 people and delivers over 100 different clinical services from a group of nine hospitals in the heart of the city.

Parexel assists clients with complex early-phase trial design and execution from first-in-human (FIH) through proof-of-concept. It has hospital-based units in the U.S., Europe and South Africa, as well as a network of alliance sites.

 

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing